Target-specific oral anticoagulants have emerged as alternative therapeutic options for the management of thrombembolic disorders. Before the development of target-specific oral anticoagulants (TSOACs ...

Factor deficiency or inhibition. The possible causes of the isolated prolonged aPTT in this case include factor deficiencies and factor inhibitors. Prolongation of both the PT and aPTT suggests ...

PITTSBURGH, PA — How does a physician manage life-threatening bleeding in patients taking dabigatran (Pradaxa, Boehringer Ingelheim), given that there is no specific antidote for the new anticoagulant ...

Advances in new reversal agents will be key for managing patients treated with DOACs to prevent major bleeding events. Given these recent new guidelines, expert consensus statements, and multiple ...

Patients with coronavirus disease 2019 (Covid-19) have a profound hypercoagulable state, and complicating venous thrombotic events are common. 1-3 Abnormalities in coagulation screening measures, ...

Ingelheim, Germany, 26. November 2015 – The European Commission has approved Praxbind® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa® (dabigatran ...

Laboratory testing for coagulation factor deficiencies and inhibitors is important for diagnosing and monitoring inherited and acquired coagulopathies and for evaluating the causes of coagulation ...

Ingelheim/Germany, 14 September 2007 – Boehringer Ingelheim today announced the publication of the RE-NOVATE study in the September 15 issue of The Lancet1. The results demonstrate that the oral ...

Please provide your email address to receive an email when new articles are posted on . Target-specific oral anticoagulants have emerged as alternative therapeutic options for the management of ...